The South and Central America organoids market is expected to reach US$ 98.85 million by 2027 from US$ 27.12 million in 2019. The market is expected to grow at a CAGR of 20.3% during 2020–2027. Increasing adoption of personalized drugs and drug discovery and growing focus on reducing animal use in researchare the major factors driving the market in the region. Additionally, increasing focus on COVID-19 research and drug discovery is likely to fuel the growth of the organoids market during the forecast period. However, thelack of skilled professionals is likely to restrain the growth of the market.
Organoids are self-organized three-dimensional tissue cultures derived from stem cells. These cultures are crafted to replicate much of the complexity of an organ or to express selected aspects of it, like producing only certain types of cells. Organoids grown from stem cells can divide indefinitely and produce various types of cells as part of their progeny. Organoids can range from less than the width of a hair to five millimeters.
Three-dimensional cultured organoids have become an important in vitro research tool that preserves genetic, phenotypic, and behavioral traits of in vivo organs. Biobanks of patient-derived organoids for many cancers and cystic fibrosis have a great value for drug development and personalized medicine. Besides, organoids hold promise for regenerative medicine too. Personalized medicine is a growing area of treatment that relies on specific drug delivery and dosing. As per a study published by PMC, personalized medicines accounted for only 5% of the new FDA approved molecular entities in 2005; whereas, they accounted for more than 25%in 2016. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past years, which is likely to increase by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical setting. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene–drug association treatment, identification of new therapies, and prediction of patient outcome.
The coronavirus pandemic has become an enormous challenge in South and Central America region, as they are low-cost regions like developing regons. These regions are widely dependent on the import of pharmaceutical and biopharmaceutical products. The lockdown situation in many countries has resulted in no trade in foreign countries. Thus, the Middle East and South and Central America countries have started producing API (active pharmaceutical ingredient) in their domestic market. However, the cost of production was a challenge for several countries. Moreover, in Brazil studies have been conductedusing in vitro models—such as stem cell-derived neural cells and cerebral organoids—to prove thatSARS-CoV-2 caninfect brain cells. SARS-CoV-2 has the ability to directly infect capillary organoids and kidney organoids, both established from human iPSCs. These observations explain the spread of the virus through the body and the loss of kidney function in severely ill individuals. Scientists are beginning to perform more experiments to explore how the COVID-19 virus replicates in the host or even test vaccines and drugs against COVID-19.
In terms of type, the intestine segment held the largest share of the organoids market in 2019.The kidney segment is expected to dominate the market during the forecast period. Chronic kidney disease is a major global health problem, as it affects 10% of the global population and kills millions of patients every year.This is expected to boost the growth of the kidney segment. The discovery of human induced pluripotent stem cells (hiPSCs) and the development of methods for the generation of 3D organoids, have opened the way for modeling human kidney development and disease in vitro, and testing new drugs directly on human tissue. Kidney organoids, derived from human pluripotent stem cells, have the potential to facilitate drug development.
Major secondary sources associated with the South and Central America organoids market report include World Health Organization, Brazilian Pharma Solutions, Food and Drug Administration, and National Center for Biotechnology Information.